Navigation Links
Response Biomedical Named Medical Device Company of the Year by LifeSciences British Columbia
Date:3/9/2009

VANCOUVER, March 9 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that it has been named the Medical Device Company of the Year by LifeSciences British Columbia. This award is presented annually by LifeSciences British Columbia to recognize an organization that has made outstanding contributions to the development of British Columbia's life sciences industry and to increase public awareness and understanding of life sciences in the province. This particular award recognizes a company for execution of business strategies, scientific excellence, leadership and vision and market position/opportunity.

"We are very pleased to be recognized for the contribution and efforts of our whole team in 2008," said S. Wayne Kay, Chief Executive Officer. "We believe we have made outstanding progress in the development, regulatory approval and partnering of our key products in the areas of infectious diseases and cardiovascular diagnostic tests and this award is very much appreciated. There are many fine companies in the life sciences sector in British Columbia and we appreciate being acknowledged amongst our peers for standing out in the achievement of major milestones last year."

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP(R) Platform for clinical and environmental applications. RAMP(R) represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.

The RAMP(R) system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP(R) clinical tests are commercially available for the early detection of heart attack, congestive heart failure and influenza.

In the non-clinical market, RAMP(R) Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development. Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000. The RAMP(R) Influenza A/B Assay and RAMP 200 reader are not yet licensed for clinical use in Canada.

Response Biomedical is a publicly traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.

About LifeSciences British Columbia

LifeSciences British Columbia supports and represents the biopharmaceutical, medical device, bioproducts, bioenergy, and greater life sciences community of British Columbia through leadership, advocacy and promotion of British Columbia's world-class science and industry. Via active facilitation of partnering and investment into the life sciences sector, British Columbia is fast becoming a global life sciences leader. LifeSciences British Columbia is a not-for-profit, non-government, industry-funded association.


'/>"/>
SOURCE Response Biomedical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AdvaMed Response to the Medical Device Safety Act
2. Ethnicity May Drive Response to Obesity, Insulin Resistance
3. Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology
4. Preparing for the Next Disaster: Dialysis Community Briefs Hill About Emergency Response
5. Statement by American Heart Association President Timothy Gardner, M.D. in Response to Health Proposals in President Obamas Budget
6. Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
7. Blunt Response to President Obamas Address
8. St John Ambulance Selects Web-Based SMS Solution From Text Messaging Centre (TMC) for Rapid Response Communication via Two-Way SMS Messaging
9. Team learns how cellular protein detects viruses and sparks immune response
10. Legion Condemns Governors Non-Response to ISSCH Proposal As Slap In The Face
11. FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center ... loss and wellness program, at their world headquarters of Omni La Costa Resort & ... results to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, cancer ... announced the center's president and CEO, Dr. Daniel Messina. , Among the recognitions, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Allergy Diagnostics Market: Scope and Methodology ... are used to determine the presence of allergens ... etc. in the samples by determining the presence ... report on global allergy diagnostics market, analyzes the ... report consists of an executive summary that provides ...
(Date:12/8/2016)... Mass. , Dec. 8, 2016   ... that Nationwide Children,s Hospital signed a ... and accelerate the development of new cures. ... organizations representing over 57 million patients globally, biopharmaceutical ... working together to improve protocol design, site selection, ...
(Date:12/8/2016)... True Health Diagnostics today announced a ... and management expertise to hospital systems throughout ... doctors and patients to benefit from state-of-the-art biomarker ... Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... to contain costs, have struggled to keep up ...
Breaking Medicine Technology: